Disclosed are exemplary embodiments of systems and methods of applying thermal interface materials (TIMs). The thermal interface materials may be applied to a wide range of substrates and components, such as lids or integrated heat spreaders of integrated circuit (IC) packages, board level shields, heat sources (e.g., a central processing unit (CPU), etc.), heat removal/dissipation structures or components (e.g., a heat spreader, a heat sink, a heat pipe, a vapor chamber, a device exterior case or housing, etc.), etc.

A deep eutectic solvent consisting of (2-hydroxyethyl) trimethyl ammonium chloride and dithiothreitol in a molar ratio of from 1:2 to 1:3 and from 0% to 10% co-solvent, and methods of enzymatic production of polypeptides using the deep eutectic solvent.

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

A system for applying thermal interface materials to components includes a supply of thermal interface material and a die. The die is operable for pushing against and/or removing a portion of the thermal interface material that is between the die and a corresponding one of the components. The portion of the thermal interface material is removed from the supply and applied to the corresponding one of the components.

A method for preparing a compound and a method for preparing a polymer employing the same are provided. The method for preparing a compound includes reacting a compound having a structure represented by Formula (I) with a compound having a structure represented by Formula (III) in the presence of a compound having a structure represented by Formula (II) to obtain a compound having a structure represented by Formula (IV) ##STR00001##
wherein Ar.sup.1 is substituted or unsubstituted aryl group; X is O, S, or NH; R.sup.1 is independently hydrogen or C.sub.1-6 alkyl group; R.sup.2 is hydroxyl group, C.sub.1-6 alkyl group, phenyl group, or tolyl group; and R.sup.3 is independently C.sub.1-6 alkyl group, C.sub.5-8 cycloalkyl group, or C.sub.2-6 alkoxyalkyl group.

A method for preparing a compound and a method for preparing a polymer employing the same are provided. The method for preparing a compound includes reacting a compound having a structure represented by Formula (I) with a compound having a structure represented by Formula (III) in the presence of a compound having a structure represented by Formula (II) to obtain a compound having a structure represented by Formula (IV) ##STR00001##
wherein Ar.sup.1 is substituted or unsubstituted aryl group; X is O, S, or NH; R.sup.1 is independently hydrogen or C.sub.1-6 alkyl group; R.sup.2 is hydroxyl group, C.sub.1-6 alkyl group, phenyl group, or tolyl group; and R.sup.3 is independently C.sub.1-6 alkyl group, C.sub.5-8 cycloalkyl group, or C.sub.2-6 alkoxyalkyl group.

A deep eutectic solvent consisting of (2-hydroxyethyl) trimethyl ammonium chloride and dithiothreitol in a molar ratio of from 1:2 to 1:3 and from 0% to 10% co-solvent, and methods of enzymatic production of polypeptides using the deep eutectic solvent.

The present invention relates to new compounds for immunogenic treatment of cancer. The compounds can be administered as a single agent or in combination with an anticancer drug including modulators of other immune pathways, especially immune checkpoint inhibitors that target CTLA-4, PD-1, and PD-L1 proteins. The compounds can produce neoantigens through irreversible protein binding in cancer cells and generate immune response.

A method for preparing a compound and a method for preparing a polymer employing the same are provided. The method for preparing a compound includes reacting a compound having a structure represented by Formula (I) with a compound having a structure represented by Formula (III) in the presence of a compound having a structure represented by Formula (II) to obtain a compound having a structure represented by Formula (IV)

##STR00001##

wherein Ar.sup.1 is substituted or unsubstituted aryl group; X is O, S, or NH; R.sup.1 is independently hydrogen or C.sub.1-6 alkyl group; R.sup.2 is hydroxyl group, C.sub.1-6 alkyl group, phenyl group, or tolyl group; and R.sup.3 is independently C.sub.1-6 alkyl group, C.sub.5-8 cycloalkyl group, or C.sub.2-6 alkoxyalkyl group.

The present invention aims to provide an immunostimulating agent superior in an immunostimulatory effect, particularly a compound useful as a vaccine adjuvant, a pharmaceutical composition containing the compound, a vaccine containing the compound and an antigen.

An immunostimulating agent containing at least one kind of a compound represented by the formula (I):

##STR00001##

wherein each symbol is as defined in the present specification, or a salt thereof.